JAGX vs MRNA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JAGX and MRNA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JAGX and MRNA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Jaguar Health, through its Napo Pharmaceuticals subsidiary, is a commercial-stage company centered on crofelemer, a plant-derived compound sourced from the Croton lechleri tree. Its approved human product, Mytesi, treats noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also has an animal-health arm, including Canalevia-CA1 for chemotherapy-induced diarrhea in dogs, and it markets Gelclair for oral mucositis. In January 2026 Jaguar out-licensed US marketing rights for Mytesi and Canalevia-CA1 to Woodward Specialty, an affiliate of privately held Future Pak, in a deal worth up to $38 million (roughly $18 million upfront plus milestones). Future Pak became the exclusive US marketer while Jaguar stays the manufacturer, giving Jaguar non-dilutive capital and letting it concentrate crofelemer development on human rare-disease indications such as intestinal failure and short bowel syndrome.

Full JAGX guide

Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.

Full MRNA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• JAGX drivers: Future Pak license and non-dilutive cash; Crofelemer rare-disease pipeline.
• MRNA drivers: Respiratory franchise beyond COVID; Oncology optionality via Merck partnership.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risks are financing and dilution. For MRNA, revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JAGX if you believe its drivers more; MRNA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JAGX and MRNA guides.

JAGX. Figures are approximate, tied to the asOf date, and distorted by one-time items and the recent reverse split, so standard valuation multiples are not very meaningful here. The Q1 2026 profit came from a one-time license fee, not sustainable operations, and per-share figures are hard to compare across reverse splits. Treat any headline number with caution and verify live data before acting; this is a speculative micro-cap where the balance sheet and financing runway matter far more than reported earnings.

MRNA. MRNA trades on pipeline potential rather than current earnings, since it is loss-making with revenue far below its pandemic peak. Traditional multiples like P/E are not meaningful while the company is unprofitable, so the market is effectively pricing the odds of flu, combination, and cancer-vaccine programs succeeding. The multibillion-dollar cash balance is a key reason the company can fund that pipeline toward its 2028 break-even goal.

Headline figures (approximate, Jul 2026): JAGX shows q1 2026 revenue ~$20.3 million, but almost entirely a one-time ~$19 million license fee, not recurring sales, recurring product revenue (q1 2026) ~$1.2 million for prescription products (Mytesi, Gelclair, Canalevia-CA1), q1 2026 net income ~$8.7 million, driven by the license fee rather than operations; net loss to common shareholders narrowed to ~$7.0 million, market capitalization Micro-cap, roughly low single-digit millions in mid-2026 (verify live before acting); MRNA shows market cap ~$20 billion, q1 2026 revenue ~$400 million, q1 2026 net loss ~$1.3 billion (incl. ~$878M legal charge), 2026 revenue growth guidance up to ~10%.

JAGX and MRNA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JAGX and MRNA exposure against your real portfolio. It is not an investment adviser.